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STELLINGEN 
Behorende bij het proefschrift “Biomarker Discovery in High 
Grade Sarcomas by Mass Spectrometry Imaging” by Sha Lou 
1. Mass spectrometry imaging (MSI) is a highly effective biomarker 
discovery tool, especially for cancer. It is arguable whether MSI can 
replace established techniques in pathology, but for sure it offers 
enormous potential to complement current histopathological 
methods (this thesis). 
2. Tumor heterogeneity is well established, both between patients 
and also within a single patient’s tumor mass. It remains one of the 
principal challenges for cancer treatment since tumor heterogeneity 
results in tumor subpopulations with different phenotypes that may 
respond differently to treatment (this thesis). 
3. Sample preparation is key to a successful MSI experiment. For 
histologically heterogeneous tumor tissues such as high-grade 
sarcomas histopathological annotation is equally important to the 
experiment’s success (this thesis). 
4. The identification and subsequent validation of the biomarkers 
discovered by MSI experiment is important. Due to current several 
challenges for definitive identification, different techniques and 
strategies must be combined (this thesis). 
5. The clinical application of MSI is highly multidisciplinary, involving 
analytical chemistry, histology, pathology, biology, bioinformatics, 
and biostatics among others and therefore collaboration is 
essential. 
6. Different omics techniques will eventually integrate in order to 
provide a more complete description of biomolecular changes 
associated with disease. 
7. High throughput molecular profiling techniques show great 
promise for identifying molecular signatures that are indicative of 
response to therapeutic treatments and disease states. 
8. New developments in instruments and/or techniques will expand 
the range of clinically useful biomarkers. 
8. It is science and technology that pushes the world forward.  
9. Take a breath before taking a decision. Deep thought is the pedal 
of life’s bicycle. 
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